medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2009, Number 3

<< Back Next >>

Residente 2009; 4 (3)

Un acercamiento a la producción de proteínas recombinantes terapéuticas de uso humano

Gamboa RA, Trujillo-Roldán MA

Language: Spanish
References: 31
Page: 87-91
PDF size: 131.30 Kb.


ABSTRACT

The use of therapeutic proteins or biopharmaceuticals for the treatment of various chronic diseases or hereditary defects, has been increasingly implemented over the past 30 years. The therapeutic proteins are produced in heterologous systems in vitro using recombinant DNA technology. Currently, new and better systems for expression are in development by implementing new plasmids, addition of genetic elements of the gene and further optimization of codons. Also, there are mutant strains which assimilate nutrients efficiently increasing the production of therapeutic recombinant proteins and/or reduce the production of toxic compounds that affect their production processes are also growing increasingly efficient to produce therapeutic proteins. The models used in industry are bacteria, yeast, insect cells and mammalian cells.


REFERENCES

  1. Villaverde A, Mattanovich D. Recombinant protein production in the new Millennium. Microb Cell Fact 2007 20; 6: 33.

  2. Betton JM, Chaffotte A. Recombinant protein folding and production. Med Sci (Paris) 2005; 21(6-7): 613-617.

  3. Yang XM, Xu L, Eppstein L. Production of recombinant human interferon-alpha 1 by Escherichia coli using a computer-controlled cultivation process. J Biotechnol 1992; 23(3): 291-301.

  4. Maldonado LM, Hernández VE, Rivero EM et al. Optimization of culture conditions for a synthetic gene expression in Escherichia coli using response surface methodology: the case of human interferon beta. Biomol Eng 2007; 24(2): 217-222.

  5. Graumann K, Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006; 1(2): 164-186.

  6. Pavlou AK, Reichert JM. Recombinant protein therapeutics success rates, market trends and values to 2010. Nat Biotechnol 2004; 22: 1513-1519.

  7. Datamonitor. Recombinant therapeutic proteins: Delivering a $53 billion mature market by 2010. 2004 May 3.

  8. Parmar HC. Biopharmaceuticals market overview. Pharmaceutical Technology Europe. 1-3-2006.

  9. San KY, Bennett GN, Aristidou AA, Chou CH. Strategies in high-level expression of recombinant protein in Escherichia coli. Ann N Y Acad Sci 1994 2; 721: 257-267.

  10. Palomares LA, Estrada-Mondaca S, Ramírez OT. Production of recombinant proteins: challenges and solutions. Methods Mol Biol 2004; 267: 15-52.

  11. Lee SY. High cell-density culture of Escherichia coli. Trends Biotechnol 1996; 14(3): 98-105.

  12. Sorensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005 26; 115(2): 113-128.

  13. Chou CP. Engineering cell physiology to enhance recombinant protein production in Escherichia coli. Appl Microbiol Biotechnol 2007; 76(3): 521-532.

  14. Ventura S, Villaverde A. Protein quality in bacterial inclusion bodies. Trends Biotechnol 2006; 24(4): 179-185.

  15. Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J 1996; 10(1): 49-56.

  16. Nuc P, Nuc K. Recombinant protein production in Escherichia coli. Biochem 2006; 52(4): 448-456.

  17. Ho JG, Middelberg AP. Estimating the potential refolding yield of recombinant proteins expressed as inclusion bodies. Biotechnol Bioeng 2004; 87(5): 584-592.

  18. Siegel RS, Brierley RA. Methylotrophic yeast Pichia pastoris produced in high-cell-density fermentations with high cell yields as vehicle for recombinant protein production. Biotechnol Bioeng 1989; 34(3): 403-404.

  19. Ramon R, Feliu JX, Cos O, Montesinos JL, Berthet FX, Valero F. Improving the monitoring of methanol concentration during high cell density fermentation of Pichia pastoris. Biotechnol Lett 2004; 26(18): 1447-1452.

  20. Kong N, Mu X, Han H, Yan W. Pilot-scale fermentation, purification, and characterization of recombinant human Oncostatin M in Pichia pastoris. Prot Express Purif 2009; 63(2): 34-39.

  21. Hartner FS, Glieder A. Regulation of methanol utilization pathway genes in yeasts. Microb Cell Fact 2006; 14: 5-39.

  22. Cregg JM, Cereghino JL, Shi J, Higgins DR. Recombinant protein expression in Pichia pastoris. Mol Biotechnol 2000; 16(1): 23-52.

  23. Bleckwenn NA, Shiloach J. Large-scale cell culture. Curr Protoc Immunol 2004 May; App 1.

  24. Chofflon M. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 2000; 7(4): 369-380.

  25. NewLab BioQuality AG. Cell line characterization. http://www newlab de 2009, May 20.

  26. Sodoyer R. Expression systems for the production of recombinant pharmaceuticals. BioDrugs 2004; 18(1): 51-62.

  27. Marcial GG. From symbiosis, a new kind of insulin. Business Week 13-8-2007.

  28. Singh V. Tech focus: Prognosticating the future of the bioreactor, specific demands will impact the ongoing evolution of this device. GEN Gen Eng Biotech News 2008; 28[2].

  29. Williams JA. Keys to a bioreactor selection. Chem Eng Prog 2002: 34-41.

  30. Park EY. Recent progress in microbial cultivation techniques. Adv Biochem Eng Biotechnol 2004; 90: 1-33.

  31. Smales CM. Therapeutic proteins: methods and protocols. Humana Press, 2005.




2020     |     www.medigraphic.com